Scil Proteins acquires Tat Phage display from ipal GmbH and Charité
Advertisement
Scil proteins announced the signing of an agreement with ipal GmbH and Charité University Hospital, Berlin for the purchase of the Tat Phage display technique. Tat Phage display allows the precise selection of Affilin® therapeutics with high affinity and selectivity for disease targets from Scil Proteins’ proprietary Affilin® libraries. Financial terms were not disclosed.
Until now, Scil Proteins’ screening process was based on the Ribosome Display technology, accessed in 2006 in a cross-licensing deal with CAT/MedImmune. The combination of Tat Phage display with Ribosome Display enhances both the speed and reliability of the screening process.
“We are delighted to have secured exclusive rights to the use of these unique state of the art screening and selection techniques,” commented Dr. Ulrike Fiedler, CEO of Scil Proteins. “This further strengthens our competitive position for the Affilin® therapeutics platform.”
Scil Proteins will use this combined screening capability to identify Affilin® lead therapeutic candidates in the core indications of cancer and inflammation/infectious diseases.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.